Rani Therapeutics enters license/supply deal with Celltrion for oral ustekinumab biosimilar

Rani Therapeutics Holdings, Inc.

Rani obtains exclusive worldwide royalty-free license to Celltrion's ustekinumab biosimilar for oral delivery using Rani's platform.
Celltrion will supply the biosimilar; Rani must purchase exclusively from Celltrion unless supply disruption.
Celltrion has right of first negotiation for commercialization after Phase 1 data package; 30-day exercise, 90-day negotiation.
Rani owns all data from research and development; can terminate for convenience; Celltrion can terminate if milestones not met.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rani Therapeutics Holdings, Inc. entered into License Agreement with Celltrion, Inc. (effective 2023-01-06).

Action: entry
Agreement: license
Counterparty: Celltrion, Inc.
Effective: 2023-01-06

Exact text from the filing

On January 6, 2023, Rani Therapeutics, LLC, an operating subsidiary of Rani Therapeutics Holdings, Inc. (“Rani”), and Celltrion, Inc. (“Celltrion”) entered into a License and Supply Agreement (the “License Agreement”).

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Rani Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000444

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.